Pascolizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pascolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIL-4
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
 ☒N☑Y (what is this?)  (verify)

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 2001/2002.[2]

References[edit]

  1. ^ Hart, TK; Blackburn, MN; Brigham-Burke, M; Dede, K; Al-Mahdi, N; Zia-Amirhosseini, P; Cook, RM (2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
  2. ^ ClinicalTrials.gov